Christiansen I, Gidlof C, Kälkner K M, Hagberg H, Bennmarker H, Tötterman T
Department of Haematology, University Hospital, Uppsala, Sweden.
Br J Haematol. 1996 Mar;92(3):639-46. doi: 10.1046/j.1365-2141.1996.00377.x.
The serum levels of soluble ICAM-1 (CD54) were significantly elevated in patients with non-Hodgkin's lymphomas (NHL, n=127) and hairy cell leukaemia (HCL, n=15) compared with healthy controls (n=31). In high-grade malignant NHL (n=79) the sICAM-1 levels correlated with the tumour mass as reflected in the Ann Arbor staging system but not with bulky disease. Further, the sICAM-1 levels correlated with disease activity as reflected by the presence of B symptoms and with other known prognostic markers. In particular serum thymidine kinase (sTK). In patients with low-grade malignant NHL (n=48) a trend towards higher serum levels of sICAM-1 was found in patients with advanced stage and B symptoms. In both low and high-grade malignant NHL, elevated levels of sICAM-1 were associated with poorer overall and disease-free survival. The present results indicated that sICAM-1 levels have a prognostic power equal to that of other serum markers claimed to be of prognostic value in NHL, namely serum lactate dehydrogenase (LDH), erythrocyte sedimentation rate (ESR), beta-2-microglobulin (beta2m), serum thymidine kinase (sTK), albumin and orosomucoid. The cellular origin and the possible interactions between soluble and surface ICAM-1 and its ligands needs further exploration.
与健康对照者（n = 31）相比，非霍奇金淋巴瘤（NHL，n = 127）和毛细胞白血病（HCL，n = 15）患者血清中可溶性细胞间黏附分子-1（CD54）水平显著升高。在高级别恶性NHL（n = 79）中，sICAM-1水平与Ann Arbor分期系统所反映的肿瘤大小相关，但与大包块疾病无关。此外，sICAM-1水平与B症状所反映的疾病活动以及其他已知的预后标志物相关，尤其是血清胸苷激酶（sTK）。在低级别恶性NHL（n = 48）患者中，晚期和有B症状的患者血清sICAM-1水平有升高趋势。在低级别和高级别恶性NHL中，sICAM-1水平升高均与较差的总生存期和无病生存期相关。目前的结果表明，sICAM-1水平的预后能力与其他声称对NHL有预后价值的血清标志物相当，即血清乳酸脱氢酶（LDH）、红细胞沉降率（ESR）、β2微球蛋白（β2m）、血清胸苷激酶（sTK）、白蛋白和血清类黏蛋白。可溶性和表面ICAM-1及其配体的细胞来源以及可能的相互作用需要进一步探索。
